Loading…
Lobbying Spend
—
Filings
31
Firms Hired
1
Active Period
2013–2020
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $30,000
Matched citations: H.R. 965
Hatch-Waxman Integrity Act of 2019
2020 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $30,000
Matched citations: H.R. 990
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $30,000
Matched citations: S. 340
Hatch-Waxman Integrity Act of 2019
2020 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $30,000
Matched citations: S. 344
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $30,000
Matched citations: S. 440
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
Hatch-Waxman Integrity Act of 2019
2019 · fourth_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 990
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · fourth_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 340
Hatch-Waxman Integrity Act of 2019
2019 · fourth_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 344
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 440
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
Hatch-Waxman Integrity Act of 2019
2019 · third_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 990
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · third_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 340
Hatch-Waxman Integrity Act of 2019
2019 · third_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 344
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 440
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
Hatch-Waxman Integrity Act of 2019
2019 · second_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 990
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · second_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 340
Hatch-Waxman Integrity Act of 2019
2019 · second_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 344
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act
Client expense: — · Firm income: $50,000
Matched citations: S. 440
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs
Client expense: — · Firm income: $40,000
Matched citations: H.R. 965
Hatch-Waxman Integrity Act of 2019
2019 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs
Client expense: — · Firm income: $40,000
Matched citations: H.R. 990
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs
Client expense: — · Firm income: $40,000
Matched citations: S. 340
Hatch-Waxman Integrity Act of 2019
2019 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs
Client expense: — · Firm income: $40,000
Matched citations: S. 344
Lower Drug Costs through Competition Act
2017 · first_quarter · Firm: VAN HEUVELEN STRATEGIES, LLC
Issues related to the CMS Part B Drugs Payment Model Demo Issues related to Zika funding Issues related to counterfeit drugs S. 297 - Increasing Competition in Pharmaceuticals Act H.R. 749 -Lower Drug Costs through Competition Act
Client expense: — · Firm income: $40,000
Matched citations: H.R. 749
Source: Senate LDA